RT Journal Article
SR Electronic
T1 Estimates of Actual and Potential Lives Saved in the United States from the use of COVID-19 Convalescent Plasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.16.24307505
DO 10.1101/2024.05.16.24307505
A1 Dragotakes, Quigly
A1 Sullivan, David J.
A1 Carter, Rickey E.
A1 Joyner, Michael J.
A1 Bloch, Evan
A1 Gebo, Kelly A.
A1 Hanley, Daniel F.
A1 Henderson, Jeffrey P.
A1 Pirofski, Liise-anne
A1 Shoham, Shmuel
A1 Senefeld, Jonathon W.
A1 Tobian, Aaron AR
A1 Wiggins, Chad C.
A1 Wright, R. Scott
A1 Paneth, Nigel S.
A1 Casadevall, Arturo
YR 2024
UL http://medrxiv.org/content/early/2024/05/18/2024.05.16.24307505.abstract
AB In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent plasma (CCP) for the treatment of hospitalized patients. Over 500,000 patients were treated with CCP during the first year of the pandemic. In this study, we used CCP weekly use, weekly national mortality data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and real-world data to estimate the number of actual inpatient lives saved by the treatment with CCP in the USA. We also estimate the potential number of lives saved if CCP had been deployed for 100% of hospitalized patients or used in 15% to 75% of outpatients. Depending on the assumptions modeled in stratified analyses, CCP was estimated to have saved between 16,187 and 66,160 lives. The ideal use of CCP might have saved as many as 215,195 lives while preventing 1,136,880 hospitalizations. CCP deployment was a successful strategy for ameliorating the impact of the COVID-19 pandemic in the USA and this experience has important implications for convalescent plasma used in future infectious disease emergencies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors